Waiting for FDA word on the approval of denosumab in postmenopausal osteoporosis, Amgen Inc. as expected has filed a biologics license application seeking approval of the highly touted subcutaneous RANK ligand inhibitor in preventing skeletal-related events (SREs) in advanced cancer patients. The news was disclosed late Friday afternoon. (BioWorld Today) Read More
